MAESTRO

Multimodal assessment of biomarkers for early diagnosis of multiple system atrophy (MSA) - MAESTRO

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON58282

Enrollment

Registered

2025-02-06

Start date

2026-01-01

Completion date

Unknown

Last updated

2026-01-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinsonism, Multiple system atrophy Parkinsonism

Interventions

neuroClues is a portable eye tracking laboratory intended to record, view, and analyze eye movements in support of identifying visual tracking impairment in human subjects.

Eligibility

Age

18 Years to 64 Years

Inclusion criteria

Inclusion criteria: Persons with a clinical suspicion of MSA (through the eyes of the referring, generically trained neurologist) but who fail to meet the current criteria for a clinically probable or established MSA diagnosis

Exclusion criteria

Exclusion criteria: Persons with an established diagnosis of PD, DLB, MSA, PSP or CBS

Design outcomes

Primary

Measure	Time frame
A) Selection of best set of biomarkers, determined at baseline, that individually have true diagnostic value in establishing an early clinical diagnosis of MSA; B) definition of an oculomotor profile in persons with MSA, also to inform analysis of study A	—

Countries

Netherlands

Contacts

Public ContactM.M. Verbeek

Radboud Universitair Medisch Centrum

secretariaatstaf.neuro@radboudumc.nl024-3614308

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Feb 3, 2026